Tocilizumab (Lokau, Kleinegger, et al., 2020; Lokau, Waetzig, et al., 2020; Okazaki et al., 2002) has previously been shown to be ineffective in mouse models, so we elected to use IL‐6‐deficient mice to model IL‐6 inhibition during post‐influenza MRSA pneumonia. Here, IL6 is linked to Methicillin-Resistant Staphylococcus Aureus Pneumonia.